<sentence id="0">Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers .</sentence>
<sentence id="1">Germline mutations of the BRCA2 gene on chromosome 13q12-q13 predispose to the development of early-onset breast cancer and ovarian cancer .</sentence>
<sentence id="2">Loss of heterozygosity detected using chromosome 13q markers in the vicinity of BRCA2 is observed in most cancers arising in carriers of germline BRCA2 mutations and also in 30-50 % of sporadic breast and ovarian cancers .</sentence>
<sentence id="3">However , somatic mutations of BRCA2 are extremely rare in sporadic cancers .</sentence>
<sentence id="4">We have examined the <scope type="spec" id="0"> <cue type="spec" id="0">hypothesis</cue> that <scope type="spec" id="1"> expression of the BRCA2 gene <cue type="spec" id="1">may</cue> be suppressed in sporadic breast cancers by a mechanism that is associated with increased methylation of cytosine residues in the promoter region</scope></scope> .</sentence>
<sentence id="5">Using a HpaII/MspI digestion-polymerase chain reaction based assay , the presence of 5-methylcytosine in three CpG dinucleotides within the BRCA2 promoter was assessed in 18 breast or ovarian cancer cell lines , in an SV40 large T antigen immortalized cell line derived from normal breast epithelial cells , in 64 primary sporadic breast cancers and peripheral blood leucocytes from these cases and in a number of other normal human tissues .</sentence>
<sentence id="6"><scope type="neg" id="2">Methylation was <cue type="neg" id="2">not</cue> detected in any of the tissues examined</scope> , <scope type="spec" id="3"> <cue type="spec" id="3">suggesting</cue> that <scope type="spec" id="4"> this mechanism of transcriptional repression is <cue type="spec" id="4">unlikely</cue> to explain the absence of somatic mutations in sporadic cancers</scope></scope> .</sentence>